Cautious Optimism As Genentech/AC Immune’s Anti-Tau Antibody Slows Cognitive Decline
Next Steps May Depend On Longer-Term Open-Label Data
Executive Summary
Semorinemab met only the cognition co-primary endpoint in the Phase II LAURIET trial in mild-to-moderate Alzheimer’s patients and missed all secondary endpoints, but some firsts were achieved in the top-line readout.
You may also be interested in...
Roche Takes Out The Alzheimer’s Trash
Deal Snapshot: Roche is finally returning the rights to two failed Alzheimer’s candidates. But why now?
Leqembi Approval Causes A Ripple Effect For Precision In Alzheimer’s
On the heels of the FDA’s full approval of Biogen and Eisai’s Leqembi, AC Immune’s CEO is hopeful that a precision medicine approach with improved diagnosis, prevention and treatment of Alzheimer’s disease is not far down the road. With 16 clinical programs, notable partnerships and wholly owned assets, AC Immune holds a strong position to help reach that destination.
Lecanemab Set A New Bar In Alzheimer’s, Now Many Drugs Are Seeking To Raise It
Drug makers are more enthusiastic than ever about the outlook for developing drugs for Alzheimer's. Scrip reports back on the latest developments at CTAD.